ABSTRACT
The clinical course of multiple sclerosis (MS) is highly variable, and the pathological changes of the disease are heterogeneous between individual patients. In recent years there has been increasing interest in developing approaches to characterizing the pathological substrates of disability in MS in the hope that quantitative indices of pathology in vivo would provide new insights into disease pathogenesis, as well as more specific and sensitive endpoints for treatment trials.
